Aerie touts silver linings from failed PhIIb, plots PhIII in dry eye disease

Aerie’s dry eye disease drug may not have met the primary endpoints it’s chosen for a Phase IIb study, but that’s not stopping the biotech from powering through Phase III — and steering toward a field with plenty of rivals.